Black Diamond Therapeutics (BDTX) Common Equity (2018 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Common Equity came in at $104.3 million in Q1 2026, down 26.3% YoY from $141.5 million in Q1 2025, and down 7.05% on a QoQ basis from $112.2 million in Q4 2025.
Black Diamond Therapeutics (BDTX) Common Equity (2018 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 9 years of Common Equity data on file, last reported at $104.3 million in Q1 2026.
- Quarterly Common Equity fell 26.3% year-over-year to $104.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $104.3 million (down 26.3% YoY) and the FY2025 annual result came in at $112.2 million, up 34.73% from the prior year.
- Common Equity declined to $104.3 million in Q1 2026, from $112.2 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $172.6 million in Q1 2022 to a low of $82.2 million in Q2 2023.
- A 5-year average of $118.7 million and a median of $115.7 million in 2022 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity plunged 46.05% — and 2025, when it soared 35.67%.
- Tracing BDTX's Common Equity over 5 years: stood at $115.7 million in 2022, then advanced by 0.9% to $116.7 million in 2023, then fell by 28.66% to $83.3 million in 2024, then surged by 34.73% to $112.2 million in 2025, then fell by 7.05% to $104.3 million in 2026.
- The last three Common Equity figures came in at $104.3 million (Q1 2026), $112.2 million (Q4 2025), and $126.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | 96.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 96.09 Mn |
| Mar 31, 2026 | 104.30 Mn |
| Dec 31, 2025 | 112.21 Mn |
| Sep 30, 2025 | 126.15 Mn |
| Jun 30, 2025 | 132.61 Mn |
| Mar 31, 2025 | 141.52 Mn |
| Dec 31, 2024 | 83.29 Mn |
| Sep 30, 2024 | 97.43 Mn |
| Jun 30, 2024 | 110.52 Mn |
| Mar 31, 2024 | 104.31 Mn |
| Dec 31, 2023 | 116.74 Mn |
| Sep 30, 2023 | 134.32 Mn |
| Jun 30, 2023 | 82.20 Mn |
| Mar 31, 2023 | 98.19 Mn |
| Dec 31, 2022 | 115.70 Mn |
| Sep 30, 2022 | 133.23 Mn |
| Jun 30, 2022 | 152.37 Mn |
| Mar 31, 2022 | 172.56 Mn |
| Dec 31, 2021 | 195.90 Mn |
| Sep 30, 2021 | 218.95 Mn |